Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:12 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 876 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Tumor-Derived FGF19

NCT06068257
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Not applicable Interventional Results available

Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy

NCT03067311
View directory record Official record
Conditions
Schizophreniform Disorders
Interventions
I-CAT, Treatment as Usual
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Carrboro, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Nov 3, 2026, 5:12 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

One Step Versus Two Step Approach for Gestational Diabetes Mellitus Screening

NCT03073330
View directory record Official record
Conditions
Gestational Diabetes
Interventions
GDM screening with 75 g 2 hour GTT, GDM screening with two step approach
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Nov 3, 2026, 5:12 AM EST
Recruiting Phase 2 Interventional

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

NCT07364071
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Radiation therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Not applicable Interventional

Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer

NCT02057029
View directory record Official record
Conditions
Breast Cancer, Early Stage Estrogen Receptor (ER) Positive Breast Cancer
Interventions
BCI Assay Results
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Not applicable Interventional Results available

My Dose Coach Mobile App to Support Insulin Titration and Maintenance

NCT04678661
View directory record Official record
Conditions
Diabetes Mellitus Type 2 - Insulin-Treated
Interventions
Smartphone application and web portal, Standard Insulin Therapy Education
Device · Behavioral
Lead sponsor
Linda Siminerio
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Nov 3, 2026, 5:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress

NCT01301105
View directory record Official record
Conditions
Focus on Pain Regulation Mechanisms, Social Stress Mechanisms, Basic Affective Mechanisms, Attention Mechanisms, Brain Mechanisms, Immune Mechanisms, Endocrine Mechanisms
Interventions
Mindfulness Based Stress Reduction (MBSR), Health Enhancement Program (HEP)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 3, 2026, 5:12 AM EST
Completed Not applicable Interventional

Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors

NCT01694225
View directory record Official record
Conditions
Breast Cancer
Interventions
bubble packaging for monthly prescription
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 3, 2026, 5:12 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Measurement of Outcome of Surgical Treatment in Patients With Acromegaly

NCT00005100
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

NCT03048279
View directory record Official record
Conditions
Multiple Endocrine Neoplasia Syndromes
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

NCT02058706
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 3, 2026, 5:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age

NCT05780047
View directory record Official record
Conditions
Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A, Phthalate Exposure, Survey
Interventions
Mail-in Urine Test for EDCs
Diagnostic Test
Lead sponsor
Million Marker Wellness, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
434 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Nov 3, 2026, 5:12 AM EST
Suspended No phase listed Observational

Magnetocardiography Endocrine Registry

NCT04739254
View directory record Official record
Conditions
Endocrine Disorder
Interventions
CardioFlux
Diagnostic Test
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting Phase 3 Interventional

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

NCT04906395
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Terminated No phase listed Observational

Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

NCT02580045
View directory record Official record
Conditions
Metastatic Cancer Patients on an Anti-cancer Therapy, Advanced Cancer, Brain Metastasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Trifecta Research Study

NCT07717866
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions
Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation
Device · Drug
Lead sponsor
Axial Therapeutic Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 1 Interventional Results available

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

NCT03238196
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Erdafitinib, Palbociclib, Fulvestrant
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • New York, New York • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Nov 3, 2026, 5:12 AM EST
Active, not recruiting Phase 2 Interventional Results available

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
View directory record Official record
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 3, 2026, 5:12 AM EST
Recruiting Phase 2 Interventional

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

NCT00580788
View directory record Official record
Conditions
Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
Interventions
PTHrP (1-36)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Nov 3, 2026, 5:12 AM EST